Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLBD Blue Bird	$56.76 -0.2%	$48.95	$30.04 ▼ $60.45	$1.80B	1.62	569,921 shs	49,144 shs
CRSP CRISPR Therapeutics	$53.53 +1.7%	$55.98	$30.04 ▼ $71.13	$4.87B	1.81	2.55 million shs	586,877 shs
GDRX GoodRx	$4.29 -0.3%	$4.55	$3.31 ▼ $8.16	$1.49B	1.23	1.98 million shs	201,182 shs
GILD Gilead Sciences	$112.92 +0.2%	$113.25	$77.74 ▼ $121.83	$140.10B	0.36	8.10 million shs	875,948 shs
VRTX Vertex Pharmaceuticals	$398.72 -0.6%	$431.31	$362.50 ▼ $519.88	$102.21B	0.44	1.64 million shs	177,452 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLBD Blue Bird	-2.57%	+0.11%	+31.29%	+45.76%	+11.16%
CRSP CRISPR Therapeutics	+1.60%	-4.05%	-6.12%	+38.40%	+10.35%
GDRX GoodRx	-1.15%	-0.69%	-5.08%	+7.23%	-45.57%
GILD Gilead Sciences	-0.23%	-1.78%	-0.42%	+3.38%	+42.67%
VRTX Vertex Pharmaceuticals	+2.55%	+3.57%	-13.23%	-10.06%	-19.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLBD Blue Bird	3.9235 of 5 stars	1.4	2.0	0.0	2.7	3.4	2.5	3.1
CRSP CRISPR Therapeutics	3.6013 of 5 stars	4.2	2.0	0.0	0.0	2.9	3.3	0.6
GDRX GoodRx	4.2227 of 5 stars	3.2	4.0	0.0	0.0	3.3	2.5	3.1
GILD Gilead Sciences	4.9797 of 5 stars	2.4	5.0	4.2	4.1	3.5	2.5	3.1
VRTX Vertex Pharmaceuticals	4.9037 of 5 stars	3.3	5.0	0.0	3.3	3.6	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLBD Blue Bird	2.89	Moderate Buy	$57.36	1.06% Upside
CRSP CRISPR Therapeutics	2.47	Hold	$71.60	33.76% Upside
GDRX GoodRx	2.45	Hold	$5.80	35.36% Upside
GILD Gilead Sciences	2.88	Moderate Buy	$115.39	2.19% Upside
VRTX Vertex Pharmaceuticals	2.56	Moderate Buy	$497.10	24.68% Upside

Current Analyst Ratings Breakdown

Latest CRSP, VRTX, BLBD, GDRX, and GILD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	VRTX Vertex Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform
8/26/2025	CRSP CRISPR Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/19/2025	GILD Gilead Sciences	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/19/2025	GILD Gilead Sciences	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$128.00
8/13/2025	BLBD Blue Bird	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/11/2025	GDRX GoodRx	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$6.00
8/8/2025	GDRX GoodRx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform
8/8/2025	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$96.00 ➝ $98.00
8/8/2025	GILD Gilead Sciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$108.00 ➝ $112.00
8/8/2025	GILD Gilead Sciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$108.00 ➝ $127.00
8/7/2025	BLBD Blue Bird	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $53.00

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLBD Blue Bird	$1.35B	1.34	$3.74 per share	15.18	$7.00 per share	8.11
CRSP CRISPR Therapeutics	$37.31M	130.49	N/A	N/A	$18.81 per share	2.85
GDRX GoodRx	$792.32M	1.88	$0.31 per share	13.67	$1.85 per share	2.32
GILD Gilead Sciences	$28.75B	4.87	$6.87 per share	16.44	$15.79 per share	7.15
VRTX Vertex Pharmaceuticals	$11.02B	9.28	N/A	N/A	$66.99 per share	5.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLBD Blue Bird	$105.55M	$3.50	16.20	11.47	1.71	8.16%	61.66%	21.26%	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	11/4/2025 (Estimated)
GDRX GoodRx	$16.39M	$0.10	42.85	23.81	1.90	4.33%	8.86%	4.50%	11/6/2025 (Estimated)
GILD Gilead Sciences	$480M	$5.02	22.49	13.92	0.70	21.86%	50.99%	17.24%	11/5/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	$13.99	28.50	22.77	N/A	31.86%	23.91%	17.14%	11/3/2025 (Estimated)

Latest CRSP, VRTX, BLBD, GDRX, and GILD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GILD Gilead Sciences	$1.96	$2.01	+$0.05	$1.55	$6.95 billion	$7.08 billion
8/6/2025	Q3 2025	BLBD Blue Bird	$0.90	$1.19	+$0.29	$1.12	$377.64 million	$398.01 million
8/6/2025	Q2 2025	GDRX GoodRx	$0.10	$0.09	-$0.01	$0.04	$205.72 million	$203.07 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million
8/4/2025	Q2 2025	VRTX Vertex Pharmaceuticals	$4.24	$4.52	+$0.28	$3.99	$2.90 billion	$2.94 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLBD Blue Bird	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
GDRX GoodRx	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.80%	N/A	62.95%	10 Years
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CRSP, VRTX, BLBD, GDRX, and GILD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	GILD Gilead Sciences	quarterly	$0.79	2.7%	9/15/2025	9/15/2025	9/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLBD Blue Bird	0.39	1.58	0.92
CRSP CRISPR Therapeutics	N/A	16.61	16.61
GDRX GoodRx	0.75	4.21	4.21
GILD Gilead Sciences	1.13	1.32	1.15
VRTX Vertex Pharmaceuticals	N/A	2.52	2.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLBD Blue Bird	93.59%
CRSP CRISPR Therapeutics	69.20%
GDRX GoodRx	63.77%
GILD Gilead Sciences	83.67%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
BLBD Blue Bird	1.10%
CRSP CRISPR Therapeutics	4.10%
GDRX GoodRx	4.17%
GILD Gilead Sciences	0.27%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLBD Blue Bird	1,948	31.71 million	31.36 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.22 million	Optionable
GDRX GoodRx	950	347.45 million	332.96 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.39 million	255.88 million	Optionable

CRSP, VRTX, BLBD, GDRX, and GILD Headlines

Recent News About These Companies

Here’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List

3 hours ago | insidermonkey.com

Vertex teams with Enlaza to expand gene therapy options

3 hours ago | thepharmaletter.comT

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by PDT Partners LLC

3 hours ago | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Stock Position Reduced by GW Henssler & Associates Ltd.

3 hours ago | marketbeat.com

1248 Management LLC Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX

4 hours ago | marketbeat.com

Paloma Partners Management Co Invests $407,000 in Vertex Pharmaceuticals Incorporated $VRTX

4 hours ago | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Royal Bank of Canada

5 hours ago | marketbeat.com

Vertex Pharmaceuticals initiated with a Market Perform at Raymond James

September 2 at 9:13 PM | msn.com

Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings

September 2 at 9:51 AM | insidermonkey.com

Flputnam Investment Management Co. Has $17.69 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX

September 2 at 9:49 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings

September 2 at 9:30 AM | finance.yahoo.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Armistice Capital LLC

September 2 at 8:12 AM | marketbeat.com

2,000 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Retirement Planning Co of New England Inc.

September 2 at 8:12 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Cyrus J. Lawrence LLC

September 2 at 8:11 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Jump Financial LLC

September 2 at 4:24 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

September 1 at 4:04 PM | finance.yahoo.com

Vident Advisory LLC Sells 3,756 Shares of Vertex Pharmaceuticals Incorporated $VRTX

September 1 at 5:52 AM | marketbeat.com

Canada Pension Plan Investment Board Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

September 1 at 5:36 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by The Manufacturers Life Insurance Company

August 31 at 7:24 AM | marketbeat.com

Te Ahumairangi Investment Management Ltd Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

August 31 at 6:51 AM | marketbeat.com

3 No-Brainer Stocks to Buy Right Now

August 31 at 6:45 AM | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP, VRTX, BLBD, GDRX, and GILD Company Descriptions

Blue Bird NASDAQ:BLBD

$56.76 -0.13 (-0.23%)

As of 10:52 AM Eastern

Blue Bird Corporation, together with its subsidiaries, designs, engineers, manufactures, and sells school buses in the United States, Canada, and internationally. The company operates through two segments, Bus and Parts. It offers Type C, Type D, and specialty buses; and alternative power options through its propane powered, gasoline powered, compressed natural gas powered, and electric powered school buses, as well as diesel engines. The company also sells replacement bus parts; and provides financing services and extended warranties related to its products. Blue Bird Corporation sells its products through drop ship and a network of dealers, as well as directly to fleet operators, the United States government, and state governments; independent service centers; and maintains a parts distribution center. Blue Bird Corporation was founded in 1927 and is headquartered in Macon, Georgia.

CRISPR Therapeutics NASDAQ:CRSP

$53.53 +0.87 (+1.65%)

As of 10:52 AM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

GoodRx NASDAQ:GDRX

$4.28 -0.02 (-0.35%)

As of 10:51 AM Eastern

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Gilead Sciences NASDAQ:GILD

$112.92 +0.21 (+0.19%)

As of 10:52 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Vertex Pharmaceuticals NASDAQ:VRTX

$398.72 -2.29 (-0.57%)

As of 10:52 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time